Alfuzosin

Abstract

Prolonged-release alfuzosin 10mg once daily controls symptoms associated with BPH throughout a 24-hour dosage interval as effectively as immediate-release alfuzosin 2.5mg three times daily but with fewer vasodilatory adverse events. A nonblind extension study showed that clinical benefits were maintained for up to 1 year and the once-daily 10mg formulation continued to be well tolerated, particularly in terms of cardiovascular effects and sexual function. Thus, for the medical management of men with BPH, prolonged-release alfuzosin 10mg is an effective, well tolerated and convenient treatment option.

Highly sensitive and rapid LC–ESI-MS/MS method for the simultaneous quantification of uroselective α1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma

“…Alfuzosin acts by inhibiting the postsynaptic alpha 1 -adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation [5][6][7][8][9].…”

Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended‐Release Tablets

“…This could be attributed to the fact that alfuzosin is wholly metabolized by liver enzymes 9 . The reported half‐life of alfuzosin range from 4.8 to 9.1 hours 15,16 . Alfuzosin undergoes extensive hepatic metabolism (up to 89% of the oral dose) via the oxidative pathways O‐demethylation and N‐dealkylation 17 .…”

“…9 The reported half-life of alfuzosin range from 4.8 to 9.1 hours. 15,16 Alfuzosin undergoes extensive hepatic metabolism (up to 89% of the oral dose) via the oxidative pathways O-demethylation and N-dealkylation. 17 In a dose-ranging study to investigate pharmacokinetic properties of alfuzosin, time to maximum concentration (t max ), maximum plasma concentration (C max ), and area under the plasma concentration-time curve from time zero to 24 hours (AUC 0-24h ) after administering a 10-mg immediate-release tablet to healthy volunteers were 2 hours, 46 ng/mL, and 332 ng • h/mL, respectively.…”

Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

“…It is presently available in three formulations: immediate-release alfuzosin 2.5 mg taken three times a day, 12 sustained-release alfuzosin 5 mg taken twice a day, 13 and prolonged-release alfuzosin 10 mg taken once a day. 14 …”